Introduction {#s1}
============

In December 2019, a series of novel coronavirus-related pneumonia cases were reported in Wuhan, China. The disease was named as coronavirus disease 2019 (COVID-19) by World Health Organization (WHO) ([@B22]). A report of 72,314 cases from the Chinese Center for Disease Control and Prevention (CDC) demonstrated that severe or critical COVID-19 cases accounted for 19% of all cases and the overall case-fatality rate was 2.3% ([@B24]), which has posed serious threats to both human health and public health services. The COVID-19 epidemic has spread rapidly, developing into a worldwide pandemic ([@B4]). Consequently, it is crucial to establish a reasonable and effective treatment strategy.

Corticosteroids, as widely used antiinflammatory agents and immunosuppressants, play an important role in the treatment of critical illness. Previous studies demonstrated that corticosteroid was used in treating coronavirus diseases, including severe acute respiratory syndrome (SARS) ([@B12]; [@B6]; [@B25]) and Middle East respiratory syndrome (MERS) ([@B2]; [@B1]); however, the safety and effectiveness remained controversial. Studies have shown that cytokine storm caused by the massive release of cytokines was the main cause of death in some cases of SARS ([@B10]) and MERS ([@B14]; [@B16]); and corticosteroids may have a certain antagonistic effect on cytokine storm ([@B13]; [@B26]). Nevertheless, the use of corticosteroids can also lead to prolonged coronavirus clearance ([@B15]) and adverse outcomes ([@B3]).

On Jan 28, 2020, WHO released interim guidance for the clinical management of COVID-19 and did not list corticosteroids as a recommended treatment ([@B23]). On Feb 8, 2020, an expert consensus from China was published and provided specific guidance for the use of corticosteroids in the treatment of COVID-19, including indications, usage, dosage, and course ([@B27]). However, the evidence for corticosteroid treatment in general clinical practice when treating COVID-19 was insufficient. Thus, this study aimed to retrospectively describe the use of corticosteroids in treating COVID-19 and thereby provided reference materials for clinicians.

Methods {#s2}
=======

Study Design and Participants {#s2_1}
-----------------------------

For this multicenter retrospective study in Hunan, China, the medical records of 488 symptomatic COVID-19 patients who were admitted to the Public Health Treatment Center of Changsha, The Central Hospital of Shaoyang, People's Hospital of Lucheng District, Huaihua First People's Hospital, Xiangtan Central Hospital, and Loudi Central Hospital between January 23^rd^, 2020 and March 8^th^, 2020 were reviewed. Subjects fulfilling eligible criteria were enrolled. The inclusion criteria included: (1) laboratory-confirmed COVID-19 cases based on the results of next-generation sequencing or real-time reverse transcription polymerase chain reaction (RT-PCR) methods, as described previously ([@B11]; 2) symptomatic for COVID-19 (fever, cough, expectoration, shortness of breath, rhinorrhea, sore throat, myalgia, chill, fatigue, headache, chest pain, conjunctival congestion, nasal congestion, nausea, vomiting, and diarrhea) ([@B7]; [@B8]; [@B11]), and fever was defined as an axillary temperature ≥37.3°C. Exclusion criteria were: (1) aged less than 18 years and (2) missing treatment details during hospitalization. All patients were divided into severe and nonsevere groups. Severe COVID-19 case was defined as dyspnea, respiratory frequency ≥30/min, blood oxygen saturation ≤93%, PaO2/FiO2 ratio \<300, and/or lung infiltrates \>50% of the lung field within 24--48 h; critical COVID-19 case was defined as patients with respiratory failure, septic shock, and/or multiple organ dysfunction/failure ([@B17]). And patients meeting the definition of severe COVID-19 case or critical COVID-19 case were categorized into the severe group, otherwise, patients were included in the nonsevere group. All sites followed the unified treatment guidelines for COVID-19 from National Health Commission of China, which have been updated since the start of the pandemic. The most updated Chinese management guideline (7^th^ edition) suggests that for patients with progressive deterioration of the oxygenation index, rapid progression on imaging, and hyperactive inflammatory reaction, corticosteroids should be used for a short period of time (3--5 days) as appropriate, and the dose should not exceed 1--2 mg/kg/day of methylprednisolone ([@B18]). The study protocol was approved by the institutional ethics committee of The Second Xiangya Hospital (2020-010) and got approvals from all other participant sites. The informed consent was waived because of the retrospective design.

Procedures and Measurements {#s2_2}
---------------------------

Baseline characteristics (age, sex, and comorbidities), signs and symptoms at admission (fever, cough, expectoration, dyspnea, temperature, and respiratory rate), laboratory findings at admission (arterial blood pH, arterial blood PaO2, white blood cell count, neutrophils, lymphocyte count, and serum lactate dehydrogenase), treatments during admission (corticosteroids, antiviral agents, antibiotics, antifungal agents, noninvasive mechanical ventilation, invasive mechanical ventilation, extracorporeal membrane oxygenation, and continuous renal replacement therapy) and disease outcomes (length of hospitalization, length of virus shedding and death) of all eligible COVID-19 patients were obtained. A unified standardized form was used to retrieve relevant data and all data were collected by a group of trained respiratory doctors. All data were checked by two physicians. Regarding corticosteroid treatment, specific data (number of patients receiving corticosteroid treatment, time from illness onset to corticosteroid therapy, time from admission to corticosteroid therapy, accumulative dose of corticosteroid therapy, mean daily dose of corticosteroid therapy, duration of corticosteroid therapy, types of corticosteroids, and routes of corticosteroid administration) were further analyzed. Doses of corticosteroid were uniformly converted to methylprednisolone by considering 4 mg of methylprednisolone and 5 mg of prednisolone as equivalent doses ([@B6]). The illness onset time was defined as the day of COVID-19 related symptoms appearing for the first time. The duration of viral shedding was defined as the time from the date of symptom onset to the date when two consecutive throat-swab with an interval more than 24 h were negative for viral species and there was no subsequent positive test ([@B28]).

Statistical Analysis {#s2_3}
--------------------

Continuous variables with a normal distribution are expressed as the mean and standard deviation (SD), while the median and interquartile range (IQR) are used to describe continuous variables with a nonnormal distribution. Categorical variables are presented as frequencies and percentages. The Chi-square test or Fisher exact test were employed to compare categorical variables. The independent sample T test was used to compare continuous variables with a normal distribution, and the Mann-Whitney U test was conducted to compare continuous variables with a nonnormal distribution. In order to adjust for confounding factors (age, sex, and comorbidities), we adopted propensity score 1:1 matching method to match patients receiving corticosteroid treatment with patients not receiving corticosteroid treatment within a caliper of 0.2 standard deviation of logit of propensity score in severe group and nonsevere group (patient numbers and characteristics of the cohorts before and after matching are available in [**Supplemental Table 1**](#ST1){ref-type="supplementary-material"}); then Mann-Whitney U test was used when comparing disease outcomes (length of hospitalization, length of viral shedding) between corticosteroid group and noncorticosteroid group. SPSS Windows Version 23.0 (IBM Corporation, Armonk, NY, USA), R software version 3.6.2 (R Foundation for Statistical Computing), and GraphPad Prism Version 7.04 (GraphPad, San Diego, CA) were used to perform statistical analysis. A two-side P-value of less than 0.05 was defined as statistically significant.

Results {#s3}
=======

A total of 450 symptomatic COVID-19 patients from six centers who fulfilled the eligible criteria were included in this retrospective study. A flow chart of this study is shown in [**Figure 1**](#f1){ref-type="fig"}. Among the 450 patients, the mean age was 46.2 ± 15.1 years, 228 (50.7%) were males, 128 (28.4%) had one or more comorbidities (hypertension, diabetes mellitus, cardiovascular disease, chronic liver disease, chronic kidney disease, cerebrovascular disease, chronic obstructive pulmonary disease, malignancy and rheumatic disease), and there were 82 severe cases and 368 nonsevere cases. The general characteristics of severe cases and nonsevere cases are shown in [**Table 1**](#T1){ref-type="table"}.

![Flow chart of this study.](fphar-11-01198-g001){#f1}

###### 

General characteristics of severe and nonsevere coronavirus disease 2019 (COVID-19) patients.

  ------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                 Overall\               Severe group\          Nonsevere group\       *P*-value
                                                            (N=450)                (N=82)                 (N=368)                
  --------------------------------------------------------- ---------------------- ---------------------- ---------------------- -----------
  Baseline characteristics                                                                                                       

  Age (years)                                               46.2 ± 15.1            56.9 ± 15.5            43.9 ± 14.0            \<0.001

  Sex, male                                                 228 (50.7)             48 (58.5)              180 (48.9)             0.115

  Any comorbidity                                           128 (28.4)             49 (59.8)              79 (21.5)              \<0.001

  Hypertension                                              75 (16.7)              31 (37.8)              44 (12.0)              \<0.001

  Diabetes mellitus                                         45 (10.0)              18 (22.0)              27 (7.3)               \<0.001

  Cardiovascular disease                                    22 (4.9)               10 (12.2)              12 (3.3)               0.002

  Chronic liver disease                                     11 (2.4)               3 (3.7)                8 (2.2)                0.695

  Chronic kidney disease                                    1 (0.2)                1 (1.2)                0 (0)                  0.182

  Cerebrovascular disease                                   11 (2.4)               5 (6.1)                6 (1.6)                0.048

  Chronic obstructive pulmonary disease                     10 (2.2)               6 (7.3)                4 (1.1)                0.002

  Malignancy                                                5 (1.1)                2 (2.4)                3 (0.8)                0.226

  Rheumatic disease                                         2 (0.4)                1 (1.2)                1 (0.3)                0.332

  Signs and symptoms at admission                                                                                                

  Fever                                                     338 (75.1)             69 (84.1)              269 (73.1)             0.036

  Cough                                                     333 (74.0)             66 (80.5)              267 (72.6)             0.139

  Expectoration                                             188 (41.8)             38 (46.3)              150 (40.8)             0.354

  Dyspnea                                                   58 (12.9)              27 (32.9)              31 (8.4)               \<0.001

  Temperature, ℃                                            36.9 (36.5--37.4)      37.2 (36.6-37.8)       36.9 (36.5--37.3)      0.004

  Respiratory rate, breaths/min                             20.0 (20.0--21.0)      20.0 (20.0--22.0)      20.0 (20.0--20.0)      \<0.001

  Laboratory findings at admission                                                                                               

  Arterial blood pH                                         7.467 (7.431--7.494)   7.480 (7.442--7.503)   7.460 (7.430--7.490)   0.030

  Arterial blood PaO2, mm Hg                                90.9 (76.2--115.0)     83.4 (63.3--104.3)     92.2 (78.8--115.3)     0.002

  White blood cell count, \*10^9^/L                         4.70 (3.61--5.82)      5.08 (4.08--6.14)      4.63 (3.58--5.71)      0.064

  Neutrophil count, \*10^9^/L                               2.93 (2.21--3.81)      3.48 (2.48--4.45)      2.84 (2.15--3.69)      0.004

  Lymphocyte count, \*10^9^/L                               1.10 (0.80--1.54)      0.82 (0.63--1.18)      1.17 (0.86--1.60)      \<0.001

  Serum lactate dehydrogenase, IU/L                         178.0 (146.1--220.3)   221.4 (176.2--318.8)   171.8 (142.8--209.0)   \<0.001

  Chest radiography at admission                                                                                                 

  Normal                                                    34 (7.6)               5 (6.1)                29 (7.9)               0.581

  Unilateral lesion                                         103 (22.9)             18 (22.0)              85 (23.1)              0.823

  Bilateral lesion                                          313 (69.6)             59 (72.0)              254 (69.0)             0.602

  Corticosteroid treatment                                                                                                       

  Number of patients receiving corticosteroid               126 (28.0)             62 (75.6)              64 (17.4)              \<0.001

  Time from illness onset to corticosteroid therapy, days   9.0 (6.0--11.0)        7.5 (5.0--11.0)        9.0 (7.0--11.0)        0.057

  Time from admission to corticosteroid therapy, days       2.0 (1.0^--^5.0)       1.0 (1.0--3.0)         4.0 (2.0--5.8)         \<0.001

  Accumulative dose of corticosteroid therapy, mg           240.0 (160.0--420.0)   340.0 (230.0--680.0)   200.0 (120.0--280.0)   \<0.001

  Median daily dose of corticosteroid therapy, mg           56.6 (40.0--78.4)      61.5 (40.0--80.0)      40.0 (40.0--60.0)      0.002

  Duration of corticosteroid therapy, days                  5.0 (3.0--7.0)         6.0 (3.8--9.3)         4.0 (3.0--5.8)         0.003

  Other treatments                                                                                                               

  Antiviral therapy                                         447 (99.3)             82 (100.0)             365 (99.2)             1.000

  Interferon                                                288 (64.0)             57 (69.5)              231 (62.8)             0.250

  Lopinavir/Ritonavir                                       351 (78.0)             68 (82.9)              283 (76.9)             0.234

  Arbidol                                                   264 (58.7)             47 (57.3)              217 (59.0)             0.784

  Ribavirin                                                 24 (5.3)               6 (7.3)                18 (4.9)               0.377

  Chloroquine phosphate                                     42 (9.3)               3 (3.7)                39 (10.6)              0.051

  Antibiotic therapy                                        225 (50.0)             71 (86.6)              154 (41.8)             \<0.001

  Quinolones                                                190 (42.2)             53 (64.6)              137 (37.2)             \<0.001

  Cephalosporins                                            22 (4.9)               12 (14.6)              10 (2.7)               \<0.001

  Carbapenems                                               8 (1.8)                7 (8.5)                1 (0.3)                \<0.001

  Macrolides                                                4 (0.9)                1 (1.2)                3 (0.8)                0.554

  Penicillins                                               33 (7.3)               22 (26.8)              11 (3.0)               \<0.001

  Linezolid                                                 6 (1.3)                6 (7.3)                0 (0)                  \<0.001

  Polymyxin                                                 1 (0.2)                1 (1.2)                0 (0)                  0.182

  Teicoplanin                                               1 (0.2)                1 (1.2)                0 (0)                  0.182

  Antifungal therapy                                        5 (1.1)                4 (4.9)                1 (0.3)                0.004

  Voriconazole                                              5 (1.1)                4 (4.9)                1 (0.3)                0.004

  Noninvasive mechanical ventilation                        16 (3.6)               16 (19.5)              0 (0)                  \<0.001

  Invasive mechanical ventilation                           10 (2.2)               10 (12.2)              0 (0)                  \<0.001

  ECMO                                                      6 (1.3)                6 (7.3)                0 (0)                  \<0.001

  CRRT                                                      6 (1.3)                6 (7.3)                0 (0)                  \<0.001

  Disease outcomes                                                                                                               

  Length of hospitalization, days                           13.0 (10.0--20.0)      18.0 (13.0--24.0)      13.0 (9.0--19.0)       \<0.001

  Length of viral shedding, days                            17.0 (13.3--24.0)      18.0 (15.0--27.5)      17.0 (13.0--23.0)      0.022

  Death                                                     3 (0.7)                3 (3.7)                0 (0)                  0.006
  ------------------------------------------------------------------------------------------------------------------------------------------

Values are presented as median (IQR), mean ± SD or number (percentage); p values were compared by Chi-square test, Fisher's exact test, independent sample T test, or Mann-Whitney U test.

ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy.

Use of Corticosteroids {#s3_1}
----------------------

In total, 126 (28.0%) patients received corticosteroid treatment. The proportion of patients in the severe group receiving such treatment was significantly higher than that in the nonsevere group (75.6% vs. 17.4%, *p*\<0.001). The median time from illness onset to corticosteroid therapy in all 126 patients was 9.0 (IQR: 6.0--11.0) days. Overall, onset time that patients received corticosteroid therapy after admission was 2.0 (IQR: 1.0--5.0) days, and the corticosteroid therapy onset time after admission was significantly later in the nonsevere group (*p*\<0.001). Moreover, the accumulative dose of corticosteroid therapy in the whole population was 240.0 (IQR: 160.0--420.0) mg. A significant difference in the median accumulative corticosteroid dose was found between the severe and nonsevere group (respectively, 340.0 vs. 200.0 mg, *p*\<0.001). The median daily dose of corticosteroid therapy in all 126 patients was 56.6 (IQR: 40.0--78.4) mg; the severe group had a significantly higher median daily dose than the nonsevere group (61.5 vs. 40.0 mg, *p*\<0.01). Regarding duration of corticosteroid therapy, the median duration in the whole population was 5.0 (IQR: 3.0--7.0) days. In contrast with the severe group, the nonsevere group demonstrated a significantly shorter median duration of therapy (4.0 vs. 6.0 days, *p*\<0.01). The types of corticosteroids used included methylprednisolone and prednisolone. Overall, 125 (99.2%) patients received methylprednisolone and one (0.8%) patient received prednisolone treatment. Regarding routes of corticosteroid administration, one (0.8%) patient took corticosteroid orally, and 125 (99.2%) were given corticosteroid intravenously. The distribution of corticosteroid treatment duration in severe and nonsevere cases is demonstrated in [**Figure 2**](#f2){ref-type="fig"}.

![Distributions of corticosteroid treatment days in severe cases (n=62) and nonsevere cases (n=64).](fphar-11-01198-g002){#f2}

Comparisons of Characteristics Between Patients Treated With and Without Corticosteroid in Nonsevere COVID-19 Cases {#s3_2}
-------------------------------------------------------------------------------------------------------------------

[**Table 2**](#T2){ref-type="table"} demonstrates comparisons of characteristics between patients treated with and without corticosteroid in nonsevere COVID-19 cases. Compared with patients who did not receive corticosteroid treatment, patients with nonsevere COVID-19 who received corticosteroid treatment were significantly older (*p*\<0.01). Regarding signs and symptoms at admission, patients with fever were more likely to receive corticosteroid treatment (*p*\<0.05). With respect to laboratory findings at admission, the arterial PaO~2~ level and lymphocyte count were significantly lower in patients treated with corticosteroids (both *p*\<0.001); in contrast, arterial blood pH and serum lactate dehydrogenase were significantly higher in patients receiving corticosteroid treatment (both *p*\<0.05). In total, 154 (41.8%) patients with nonsevere COVID-19 received antibiotic therapy; and 58.8% of patients initiated antibiotic treatment no earlier than corticosteroid treatment. The proportion of patients in the corticosteroid group receiving antibiotic therapy was significantly higher than that in the noncorticosteroid group (79.7% vs. 33.9%, *p*\<0.001). Quinolones were the most widely used antibiotics in nonsevere COVID-19 cases, followed by cephalosporins, penicillins, macrolides, and carbapenems. All 64 patients who received corticosteroid treatment survived, and 304 cases in the noncorticosteroid group also survived ([**Table 2**](#T2){ref-type="table"}). Furthermore, hospitalization length and viral shedding time of patients in the corticosteroid group were significantly longer than those in patients in the noncorticosteroid group after adjusting for baseline characteristics, including age, sex, and comorbidities (both *p*\<0.05) ([**Tables 4**](#T4){ref-type="table"} and [**5**](#T5){ref-type="table"}).

###### 

Comparisons of characteristics between patients treated with and without corticosteroid in nonsevere coronavirus disease 2019 (COVID-19) cases.

  -----------------------------------------------------------------------------------------------------------------------------
  Variables                               Overall\               Corticosteroid group\   Noncorticosteroid group\   *P*-value
                                          (N=368)                (N=64)                  (N=304)                    
  --------------------------------------- ---------------------- ----------------------- -------------------------- -----------
  Baseline characteristics                                                                                          

  Age (years)                             42.0 (33.0--51.0)      49.5 (39.0--61.0)       41.0 (32.0--50.0)          0.001

  Sex, male                               180 (48.9)             34 (53.1)               146 (48.0)                 0.458

  Any comorbidity                         79 (21.5)              19 (29.7)               60 (19.7)                  0.078

  Hypertension                            44 (12.0)              12 (18.8)               32 (10.5)                  0.065

  Diabetes mellitus                       27 (7.3)               6 (9.4)                 21 (6.9)                   0.671

  Cardiovascular disease                  12 (3.3)               5 (7.8)                 7 (2.3)                    0.062

  Chronic liver disease                   8 (2.2)                2 (3.1)                 6 (2.0)                    0.918

  Chronic kidney disease                  0 (0)                  0 (0)                   0 (0)                      NA

  Cerebrovascular disease                 6 (1.6)                5 (7.8)                 1 (0.3)                    \<0.001

  Chronic obstructive pulmonary disease   4 (1.1)                2 (3.1)                 2 (0.7)                    0.141

  Malignancy                              3 (0.8)                0 (0)                   3 (1.0)                    1.000

  Rheumatic disease                       1 (0.3)                0 (0)                   1 (0.3)                    1.000

  Signs and symptoms at admission                                                                                   

  Fever                                   269 (73.1)             54 (84.4)               215 (70.7)                 0.025

  Cough                                   267 (72.6)             50 (78.1)               217 (71.4)                 0.272

  Expectoration                           150 (40.8)             27 (42.2)               123 (40.5)                 0.798

  Dyspnea                                 31 (8.4)               6 (9.4)                 25 (8.2)                   0.763

  Temperature, ℃                          36.9 (36.5--37.3)      36.9 (36.5--37.6)       36.9 (36.5--37.3)          0.516

  Respiratory rate, breaths/min           20.0 (20.0--20.0)      20.0 (20.0--20.3)       20.0 (20.0--20.0)          0.054

  Laboratory findings at admission                                                                                  

  Arterial blood pH                       7.460 (7.430--7.490)   7.475 (7.445--7.505)    7.460 (7.428--7.487)       0.033

  Arterial blood PaO2, mm Hg              92.2 (78.8--115.3)     79.5 (68.1--95.4)       94.3 (82.0--120.0)         \<0.001

  White blood cell count, \*10^9^/L       4.63 (3.58--5.71)      4.59 (3.55--5.95)       4.64 (3.58--5.68)          0.932

  Neutrophil count, \*10^9^/L             2.84 (2.15--3.69)      3.03 (2.38--3.93)       2.80 (2.13--3.61)          0.082

  Lymphocyte count, \*10^9^/L             1.17 (0.86--1.60)      0.95 (0.73--1.26)       1.21 (0.89--1.65)          \<0.001

  Serum lactate dehydrogenase, IU/L       171.8 (142.8--209.0)   182.0 (149.1--242.0)    170.8 (141.9--206.0)       0.047

  Chest radiography at admission                                                                                    

  Normal                                  29 (7.9)               3 (4.7)                 26 (8.6)                   0.297

  Unilateral lesion                       85 (23.1)              2 (3.1)                 83 (27.3)                  \<0.001

  Bilateral lesion                        254 (69.0)             59 (92.2)               195 (64.1)                 \<0.001

  Treatments                                                                                                        

  Antiviral therapy                       365 (99.2)             64 (100.0)              301 (99.0)                 1.000

  Interferon                              231 (62.8)             36 (56.3)               195 (64.1)                 0.235

  Lopinavir/Ritonavir                     283 (76.9)             47 (73.4)               236 (77.6)                 0.469

  Arbidol                                 217 (59.0)             42 (65.6)               175 (57.6)                 0.234

  Ribavirin                               18 (4.9)               5 (7.8)                 13 (4.3)                   0.383

  Chloroquine phosphate                   39 (10.6)              9 (14.1)                30 (9.9)                   0.322

  Antibiotic therapy                      154 (41.8)             51 (79.7)               103 (33.9)                 \<0.001

  Quinolones                              137 (37.2)             45 (70.3)               92 (30.3)                  \<0.001

  Cephalosporins                          10 (2.7)               3 (4.7)                 7 (2.3)                    0.520

  Carbapenems                             1 (0.3)                1 (1.6)                 0 (0)                      0.174

  Macrolides                              3 (0.8)                1 (1.6)                 2 (0.7)                    0.437

  Penicillins                             11 (3.0)               6 (9.4)                 5 (1.6)                    0.004

  Linezolid                               0 (0)                  0 (0)                   0 (0)                      NA

  Polymyxin                               0 (0)                  0 (0)                   0 (0)                      NA

  Teicoplanin                             0 (0)                  0 (0)                   0 (0)                      NA

  Antifungal therapy                      1 (0.3)                1 (1.6)                 0 (0)                      0.174

  Voriconazole                            1 (0.3)                1 (1.6)                 0 (0)                      0.174

  Noninvasive mechanical ventilation      0 (0)                  0 (0)                   0 (0)                      NA

  Invasive mechanical ventilation         0 (0)                  0 (0)                   0 (0)                      NA

  ECMO                                    0 (0)                  0 (0)                   0 (0)                      NA

  CRRT                                    0 (0)                  0 (0)                   0 (0)                      NA
  -----------------------------------------------------------------------------------------------------------------------------

Values are presented as median (IQR) or number (percentage); p values were compared by Chi-square test, Fisher's exact test, or Mann-Whitney U test.

ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; NA, not available.

Comparisons of Characteristics Between Patients Treated With and Without Corticosteroid in Severe COVID-19 Cases {#s3_3}
----------------------------------------------------------------------------------------------------------------

[**Table 3**](#T3){ref-type="table"} shows comparisons of characteristics between patients treated with and without corticosteroid in severe COVID-19 cases. Among the 82 patients with severe COVID-19, patients treated with corticosteroids were significantly older and were significantly more likely to present comorbidities at admission (both *p*\<0.05). Patients with fever were significantly more likely to be treated with corticosteroids (*p*\<0.05). The levels of arterial blood pH and serum lactate dehydrogenase in the corticosteroid group were significantly higher than those in the noncorticosteroid group (both *p*\<0.05). 71 (86.6%) patients with severe COVID-19 received antibiotic therapy; and 62.7% of patients initiated antibiotic treatment no earlier than corticosteroid treatment. The proportion of patients in the corticosteroid group who received antibiotic therapy was significantly higher than that in the noncorticosteroid group (*p*\<0.001). Quinolones were the most widely used antibiotics in severe COVID-19, followed by penicillins, cephalosporins, carbapenems, and linezolid. Of the 62 patients who received corticosteroid treatment, three (4.8%) died; however, 20 patients in the noncorticosteroid group all survived. No significant difference in hospitalization length or viral shedding time was found between the two groups after adjusting for baseline characteristics, including age, sex, and comorbidities (*p*\>0.05) ([**Table 4**](#T4){ref-type="table"} and [**5**](#T5){ref-type="table"}). The clinical information of fatal cases is shown in [**Supplemental Table 2**](#ST2){ref-type="supplementary-material"}.

###### 

Comparisons of characteristics between patients treated with and without corticosteroid in severe coronavirus disease 2019 (COVID-19) cases.

  -----------------------------------------------------------------------------------------------------------------------------
  Variables                               Overall\               Corticosteroid group\   Noncorticosteroid group\   *P*-value
                                          (N=82)                 (N=62)                  (N=20)                     
  --------------------------------------- ---------------------- ----------------------- -------------------------- -----------
  Baseline characteristics                                                                                          

  Age (years)                             56.9 ± 15.5            54.5 ± 15.3             64.5 ± 14.1                0.011

  Sex, male                               48 (58.5)              36 (58.1)               12 (60.0)                  0.879

  Any comorbidity                         49 (59.8)              32 (51.6)               17 (85.0)                  0.008

  Hypertension                            31 (37.8)              21 (33.9)               10 (50.0)                  0.196

  Diabetes mellitus                       18 (22.0)              13 (21.0)               5 (25.0)                   0.946

  Cardiovascular disease                  10 (12.2)              7 (11.3)                3 (15.0)                   0.962

  Chronic liver disease                   3 (3.7)                3 (4.8)                 0 (0)                      1.000

  Chronic kidney disease                  1 (1.2)                0 (0)                   1 (5.0)                    0.244

  Cerebrovascular disease                 5 (6.1)                2 (3.2)                 3 (15.0)                   0.169

  Chronic obstructive pulmonary disease   6 (7.3)                3 (4.8)                 3 (15.0)                   0.306

  Malignancy                              2 (2.4)                2 (3.2)                 0 (0)                      1.000

  Rheumatic disease                       1 (1.2)                0 (0)                   1 (5.0)                    0.244

  Signs and symptoms at admission                                                                                   

  Fever                                   69 (84.1)              56 (90.3)               13 (65.0)                  0.019

  Cough                                   66 (80.5)              47 (75.8)               19 (95.0)                  0.119

  Expectoration                           38 (46.3)              29 (46.8)               9 (45.0)                   0.890

  Dyspnea                                 27 (32.9)              19 (30.6)               8 (40.0)                   0.439

  Temperature, ℃                          37.3 ± 0.9             37.4 ± 0.9              37.0 ± 0.7                 0.069

  Respiratory rate, breaths/min           20.0 (20.0-22.0)       20.0 (20.0--22.0)       20.5 (20.0--22.0)          0.943

  Laboratory findings at admission                                                                                  

  Arterial blood pH                       7.480 (7.442--7.503)   7.483 (7.451--7.509)    7.450 (7.427--7.480)       0.033

  Arterial blood PaO2, mm Hg              83.4 (63.3--104.3)     85.8 (64.4--113.3)      71.1 (56.1--83.0)          0.092

  White blood cell count, \*10^9^/L       5.51 ± 2.74            5.38 ± 2.27             5.90 ± 3.89                0.469

  Neutrophil count, \*10^9^/L             3.48 (2.48--4.45)      3.53 (2.75--4.59)       2.96 (2.29--3.66)          0.180

  Lymphocyte count, \*10^9^/L             0.82 (0.63--1.18)      0.80 (0.62--1.14)       0.97 (0.66--1.39)          0.259

  Serum lactate dehydrogenase, IU/L       221.4 (176.2--318.8)   247.0 (177.9--349.0)    190.1 (149.0--217.0)       0.017

  Chest radiography at admission                                                                                    

  Normal                                  5 (6.1)                2 (3.2)                 3 (15.0)                   0.169

  Unilateral lesion                       18 (22.0)              9 (14.5)                9 (45.0)                   0.011

  Bilateral lesion                        59 (72.0)              51 (82.3)               8 (40.0)                   \<0.001

  Treatments                                                                                                        

  Antiviral therapy                       82 (100.0)             62 (100.0)              20 (100.0)                 NA

  Interferon                              57 (69.5)              43 (69.4)               14 (70.0)                  0.957

  Lopinavir/Ritonavir                     68 (82.9)              55 (88.7)               13 (65.0)                  0.035

  Arbidol                                 47 (57.3)              32 (51.6)               15 (75.0)                  0.066

  Ribavirin                               6 (7.3)                5 (8.1)                 1 (5.0)                    1.000

  Chloroquine phosphate                   3 (3.7)                3 (4.8)                 0 (0)                      1.000

  Antibiotic therapy                      71 (86.6)              59 (95.2)               12 (60.0)                  \<0.001

  Quinolones                              53 (64.6)              47 (75.8)               6 (30.0)                   \<0.001

  Cephalosporins                          12 (14.6)              8 (12.9)                4 (20.0)                   0.677

  Carbapenems                             7 (8.5)                7 (11.3)                0 (0)                      0.267

  Macrolides                              1 (1.2)                0 (0)                   1 (5.0)                    0.244

  Penicillins                             22 (26.8)              19 (30.6)               3 (15.0)                   0.170

  Linezolid                               6 (7.3)                5 (8.1)                 1 (5.0)                    1.000

  Polymyxin                               1 (1.2)                1 (1.6)                 0 (0)                      1.000

  Teicoplanin                             1 (1.2)                1 (1.6)                 0 (0)                      1.000

  Antifungal therapy                      4 (4.9)                4 (6.5)                 0 (0)                      0.568

  Voriconazole                            4 (4.9)                4 (6.5)                 0 (0)                      0.568

  Noninvasive mechanical ventilation      16 (19.5)              16 (25.8)               0 (0)                      0.027

  Invasive mechanical ventilation         10 (12.2)              9 (14.5)                1 (5.0)                    0.461

  ECMO                                    6 (7.3)                6 (9.7)                 0 (0)                      0.341

  CRRT                                    7 (8.5)                6 (9.7)                 1 (5.0)                    0.849
  -----------------------------------------------------------------------------------------------------------------------------

Values are presented as median (IQR),mean ± SD or number (percentage); p values were compared by Chi-square test, Fisher's exact test, independent sample T test, or Mann-Whitney U test.

ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; NA, not available.

###### 

Comparisons of length of hospitalization in nonsevere and severe coronavirus disease 2019 (COVID-19) cases using propensity score 1:1 matching.

  Variables                         Before matching     After matching                                                        
  --------------------------------- ------------------- ------------------- --------- ------------------- ------------------- ---------
  Nonsevere group                                                                                                             
  Number of cases                   64                  304                           60                  60                  
  Length of hospitalization, days   19.0 (14.0--25.0)   12.0 (9.0--17.0)    \<0.001   19.0 (14.0--25.0)   11.5 (9.0--17.0)    \<0.001
  Severe group                                                                                                                
  Number of cases                   59                  20                            20                  20                  
  Length of hospitalization, days   20.0 (13.0--28.0)   16.0 (11.0--22.5)   0.091     14.0 (11.3--25.5)   16.0 (11.0--22.0)   0.883

Values are presented as median (IQR) or number; p values were compared by Mann-Whitney U test.

###### 

Comparisons of length of viral shedding in nonsevere and severe coronavirus disease 2019 (COVID-19) cases using propensity score 1:1 matching.

  Variables                        Before matching     After matching                                                      
  -------------------------------- ------------------- ------------------- ------- ------------------- ------------------- -------
  Nonsevere group                                                                                                          
  Number of cases                  63                  244                         55                  55                  
  Length of viral shedding, days   20.0 (16.0--26.0)   17.0 (13.0--22.0)   0.001   20.0 (16.0--25.0)   17.0 (13.0--22.0)   0.046
  Severe group                                                                                                             
  Number of cases                  53                  12                          11                  11                  
  Length of viral shedding, days   19.0 (16.0--28.5)   17.5 (13.0--22.8)   0.123   23.0 (16.0--31.0)   18.0 (13.0--23.0)   0.101

Values are presented as median (IQR) or number; p values were compared by Mann-Whitney U test.

Discussion {#s4}
==========

To the best of our knowledge, this is the first multicenter retrospective study to describe the use of corticosteroids in treating COVID-19. Our data demonstrate that median daily dose of methylprednisolone in general clinical practice was 56.6 mg and median corticosteroid therapy duration was 5.0 days, which are consistent with recommendations in the updated Chinese management guideline ([@B18]). However, indications for corticosteroid treatment in the guideline are flexible, and corticosteroid use, to some extent, relies on physicians' judgments of patients' disease progression. Thus, a proportion of nonsevere COVID-19 patients may also receive corticosteroid treatment, although they may not meet the definition of severe disease outlined in the Chinese management guideline. In this study, 64 (17.4%) out of 368 nonsevere cases received corticosteroid treatment, while 62 (75.6%) out of 82 severe cases received corticosteroid treatment. We may speculate that corticosteroids are regarded as one of treatments in the general clinical practice of COVID-19, especially in severe cases.

The validity and rationality of corticosteroids in the treatment of coronavirus diseases have always been controversial. A retrospective study by [@B6] found that corticosteroid use was significantly related to lower mortality, longer survival time, and shorter hospital stay in critical SARS patients and was not associated with the incidence of complications. [@B2] found that corticosteroid therapy in patients with MERS was not associated with a difference in mortality after adjustment for time-varying confounders. However, [@B1] reported that the use of corticosteroids contributed to increased mortality in MERS patients. Regarding COVID-19, a retrospective study involving 46 patients demonstrated that early, low-dose and short-term application of corticosteroid was associated with a faster improvement of clinical symptoms and absorption of lung focus ([@B21]); nevertheless, the relatively small sample size and retrospective design limited the interpretation of the study results. Recently, a large-scale and well-designed randomized clinical trial (UK Recovery trial) demonstrated that the proper use of dexamethasone (low-to-moderate dose of 6 mg per day for 10 days) significantly reduced deaths by one-third in patients receiving invasive mechanical ventilation and by one-fifth in other patients who only received oxygen without invasive mechanical ventilation; however, no benefit was observed among those patients who did not require respiratory support ([@B9]). UK Recovery trial brings a breakthrough in treating severe COVID-19 patients. As far as we know, there has been no attempt of using dexamethasone to treat COVID-19 patients in China; and it is expected that the practical corticosteroid treatment strategy in UK Recovery trial can be verified and popularized worldwide as soon as possible. In this study, the proportion of patients in the severe group receiving corticosteroid treatment was significantly higher than that in the nonsevere group. However, we could not compare our study findings with the UK RECOVERY trial findings since it was not possible to assess the association between corticosteroid use and mortality in our study due to: 1) low death rate among the study cohort; 2) the study was designed and aimed to describe the use of corticosteroids among COVID-19 patients rather than assessing the association between corticosteroid use and mortality outcome; and 3) the type and duration of corticosteroids in this study is different from UK RECOVERY trial.

After the invasion of coronavirus, there are two kinds of inflammatory reaction mechanisms: protective and pathogenic. The pathogenic inflammatory reaction is caused by the massive infiltration of inflammatory cells (monocyte macrophage, neutrophils), release of cytokines, replication of virus, and delay of the interferon reaction, which leads to a decrease in cellular and humoral immunity, significant enhancement of apoptosis, increase in vascular leakage, and the limited virus clearance, and can further result in acute lung injury (ALI), acute respiratory distress syndrome (ARDS), and even death ([@B5]). Previous cases of SARS and MERS have proven that the cytokine storm caused by the release of a large number of cytokine was the main cause of death ([@B10]; [@B14]; [@B16]). Cytokine storm refers to the phenomenon where a variety of cytokines in body fluid, such as TNF-α, IL-1, and IL-6, are produced rapidly after an organism is infected and is an important cause of ARDS and multiple organ failure ([@B19]). [@B10] showed that cytokine storm was involved in the immune damage seen in SARS patients after virus infection. Levels of IFN - γ, IL-18, TGF-β, IL-6, IP-10, MCP-1, MIG and IL-8 were significantly increased in SARS patients; and levels of IL-18, IP-10, MIG and MCP-1 in dead patients were higher than those in living patients ([@B10]). Two studies by Korean scholars have proven that there is also a significant increase of cytokines (IL-6, IFN-α, IL-8, CXCL10 and CCL5) in patients with MERS, which may lead to a potential cytokine storm ([@B14]; [@B16]). [@B11] reported that the initial plasma concentrations of IL-1 β, IL-7, IL-8, IL-9, IL-10, FGF, GCSF, GMCSF, IFN-γ, IP10, MCP1, MIP1A, MIP1B, PDGF, TNF-α, and VEGF in COVID-19 patients were higher than those in healthy adults, and plasma concentrations of IL-2, IL-7, IL-10, GCSF, IP10, MCP1, MIP1A, and TNF-α in ICU patients were significantly higher when comparing with non-ICU patients. Corticosteroid may have a certain antagonistic effect on cytokine storm. The effect of corticosteroid on systemic cytokine storm has been confirmed in animal models. Saif LJ et al. used pigs infected with coronavirus as models to explore the effect of corticosteroid use on disease models. The results revealed that the number of IFN-γ cytokine secreting cells (CSC cells) in the spleen, tracheobronchial lymph nodes, and blood was lower in the disease model group with dexamethasone intervention than that in the disease model group without corticosteroid intervention, and the secretion of IFN-γ, IFN-α, IL-6, and other cytokines in the disease model group with dexamethasone intervention was inhibited to varying degrees in different periods ([@B13]; [@B26]).

Infections accompanying corticosteroid use in coronavirus diseases are also worthy of attention. [@B12] pointed out that six SARS patients who received corticosteroid shock therapy (daily pulsed administration of 0.5--1.0 g of methylprednisolone for two to three days) had multiple hospital infections and suggested careful corticosteroid use with appropriate antibiotic coverage and microbiological monitoring are of great importance in treating SARS patients. [@B20] reported the case of a 39-year-old man with fatal fungal infection in multiple organs after repeated, long-term, and high-dose glucocorticoid treatment, who finally died due to ineffective clinical treatment; this case suggests that inappropriate use of large dose and long-term corticosteroid can severely inhibit the immune function of SARS patients. In this study, we observed the proportion of patients receiving antibiotic therapy in the corticosteroid group was significantly higher than in the noncorticosteroid groups, and this was apparent in both severe and nonsevere groups. Moreover, there may be a relationship between corticosteroid and antibiotic use, as 60.9% of patients initiated antibiotic treatment no earlier than corticosteroid treatment. Nevertheless, there is a lack of specific recommendations for antibiotics and antifungal agents in the current guideline, and more studies are warranted to provide evidence regarding this issue.

Furthermore, our results demonstrated a significant prolonged viral shedding time existed in nonsevere patients receiving corticosteroid treatment. A randomized controlled study involving 16 nonsevere SARS patients found that the early application of corticosteroid (within 7 days of onset) was related to the delayed clearance of SARS virus in the plasma; the plasma viral RNA concentration in the hormone intervention group was significantly higher than that in the control group at the 2nd and 3rd weeks ([@B15]). Another retrospective study on critically ill patients with MERS indicated that after adjusting for confounding factors such as baseline and starting time of corticosteroid therapy, corticosteroid application was significantly associated with delayed clearance time of MERS virus RNA in patients' plasma; furthermore, there was statistical difference between subgroups with different doses of corticosteroid therapy ([@B2]).

Some limitations exist in this study. First, this is a retrospective descriptive study rather than a prospective study; More large-scale randomized placebo-controlled studies should be performed to provide evidence in treating COVID-19. Second, we were unable to directly report the complications of bacterial and fungal infections that were related to corticosteroid use due to the lack of pathogen evidence from blood or sputum culture. Instead, we summarized the proportion of antibiotic and antifungal agents use to indirectly reflect complications of bacterial and fungal infections. Third, because of the limited sample size of fatal COVID-19 cases in this study, we did not use logistic or Cox regression model to explore potential factors related to mortality in COVID-19.

Conclusion {#s5}
==========

Our study indicates that corticosteroids are regarded as one of treatments in the general clinical practice of COVID-19. However, corticosteroid use may be accompanied by increased use of antibiotics, longer hospitalization, and prolonged viral shedding.
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